Clinical Trial Update: A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old [Phase 3]

View source ↗

Summary

A Phase 3 randomized study evaluating gemtuzumab ozogamicin added to daunorubicin and cytarabine in untreated acute myeloid leukemia patients aged 50-70 years; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin (daunorubicin)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: Acute Leukemia French Association | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED